Ernumab is an innovative active substance, produced in injection form, created to prevent and reduce the pain intensity of migraine in people with 4 or more episodes per month. This drug is the first and only monoclonal antibody designed specifically for migraine prevention and has already been approved in the United States, under the trade name Aimovig.
Migraine is characterized by a severe, throbbing headache that can only reach one side and can be accompanied by other symptoms such as nausea, vomiting, dizziness, light sensitivity, neck pain and difficulty concentrating. Learn more about migraine symptoms.
- The results of studies with erenumab were very positive.
- With a halving of the number of migraines and also the duration of pain episodes.
- With dosing of 70 mg and 140 mg.
- In addition.
- This drug was well tolerated and no side effects were reported.
Ernumab is a human monoclonal antibody that works by blocking the receptor of peptides linked to the calcitonin gene, which is a chemical compound present in the brain and is involved in the activation of migraine and the duration of pain.
Peptide related to the calcitonin gene is thought to play a key role in migraine pathophysiology, with the link to its receptors involved in the transmission of migraine pain. In migraine patients, migraine levels increase at the beginning of the episode, returning to normal after pain relief, with medication treatment used to treat migraine, or when the attack goes away.
Therefore, erenumab can not only reduce migraine episodes, but can also reduce the intake of medications currently used to treat migraines, which have many side effects.
Aimovig should be injected under the skin with a syringe or a pre-filled pen, which can be administered by the person after proper training.
The recommended dose is 70 mg every 4 weeks, in a single injection. In some cases, a dose of 140 mg may be required every 4 weeks.
The most common side effects that can occur during treatment with erenumab are injection site reactions, constipation, muscle spasms and itching.
Aimovig is contraindicated in people with hypersensitivity to one of the components of the formula and is not recommended for pregnant or lactating women.